SIG IVÆRKSÆTTER TILBAGEKØB AF EGNE AKTIER
Bestyrelsen for SIG har i forlængelse af offentliggørelsen af periodemeddelelsen for Q3-2022, besluttet at iværksætte et aktietilbagekøb for maksimalt DKK 5 mio.
SIG ejer pr. dags dato 5.551.241 egne aktier svarende til 10,36 % af selskabets aktiekapital. Det samlede antal aktier i virksomheden er i alt 53.566.497 aktier, inklusive egne aktier.
Selskabet har (Jf. selskabsmeddelelse 15/2022), præsteret en indtjening på DKK 27.1 mio. efter skat for perioden 1. januar 2022 – 31 oktober 2022.
Grundlag for tilbagekøbet:
På selskabets ordinære generalforsamling den 23. april 2019 blev selskabet bemyndiget til at købe egne aktier. Bemyndigelsen har følgende ordlyd:
"På generalforsamlingen den 23. april 2019 blev selskabet bemyndiget til at købe egne aktier gældende for en periode på 5 år at regne fra datoen for generalforsamlingsgodkendelsen. Der blev givet bemyndigelse til at erhverve egne aktier op til det punkt, hvor den nominelle værdi af selskabets samlede beholdning af egne aktier udgør 25% af selskabets nominelle aktiekapital. Selskabet må ikke erhverve egne aktier til under kurs pari, og selskabet må højst betale en pris, der svarer til den senest noterede handelskurs på Nasdaq Copenhagen forud for handlens indgåelse tillagt 10%"
Med iværksættelsen af aktietilbagekøbet vil bestyrelsen benytte bemyndigelsen til at lade selskabet erhverve egne aktier. De tilbagekøbte aktier kan anvendes til afdækning af selskabets warrantprogram af 1. maj 2020 (Jf. selskabsmeddelelse 20/2020), annulleres eller sælges til 3 part.
Beslutning herom vil bestyrelsen efterfølgende vurdere ift. hvad som skaber højst mulig værdi for aktionærerne på det givne tidspunkt.
Beskrivelse af tilbagekøbet:
Aktietilbagekøbet løber i perioden fra mandag d. 21. november 2022 kl. 09.00 til og med fredag d. 16. december 2022 klokken 17:00 (dansk tid).
Selskabet vil hver fredag efter markedsluk meddele om ugens samlede resultat af aktietilbagekøb med offentliggørelse af alle handler, restbeløb i rammen samt hvor stort et ejerskab man besidder af selskabets aktiekapital.
Selskabet kan ligeledes vælge at stoppe aktietilbagekøbsprogrammet når som helst enten fordi den maksimale ramme er forbrugt eller hvis der indtræffer væsentlige kurspåvirkende hændelser inden periodens udløb d. 16. december 2022.
SIG har valgt ikke at anvende Safe Harbour reglerne i forbindelse med aktietilbagekøbsprogrammet, men vil i stedet købe aktier direkte i markedet struktureret på en måde, så Safe Harbour principperne følges bedst muligt. SIG vil i aktietilbagekøbet dog fravige den traditionelle Safe Habour regel om maksimalt at erhverve 25% af dagsomsætningen henset til aktiens lave likviditet.
Kontakt:
Evt. spørgsmål til denne meddelelse kan rettes til CEO Michael Hove på 28126609 eller mail mh@sca-inv-group.dk
Venlig hilsen
Bestyrelsen
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Inteleos to Host Roundtable on Advancing Maternal Health through Point-Of-Care-Ultrasound Certification6.5.2024 23:25:48 CEST | Press release
Global healthcare certification leader convenes experts to discuss ultrasound training and certification as key strategy to reduce maternal mortality ROCKVILLE, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, will host a roundtable discussion titled "Advancing Maternal and Fetal Health through POCUS Training and Certification" on May 29 alongside a side event during the WHO World Health Assembly and the AI for Good Global Summit. The roundtable will explore the urgent need to expand point-of-care ultrasound (POCUS) training and certification for frontline maternal health clinicians as a crucial intervention for reducing preventable maternal deaths and achieving UN Sustainable Development Goals, and how to implement to scale. Despite the increased availability of affordable ultrasound technology, there remains a significant training gap that limits access to this diagnostic tool, especially in low-resource areas with high matern
ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release
SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release
If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and
Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra
Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342